Skip to main content
Erschienen in: Strahlentherapie und Onkologie 4/2018

08.12.2017 | Original Article

ÖGRO survey on radiotherapy capacity in Austria

Status quo and estimation of future demands

verfasst von: Dr. Brigitte Zurl, Anja Bayerl, Alexander De Vries, Hans Geinitz, Robert Hawliczek, Tomas-Henrik Knocke-Abulesz, Peter Lukas, Richard Pötter, Wolfgang Raunik, Brigitte Scholz, Annemarie Schratter-Sehn, Felix Sedlmayer, Dietmar Seewald, Edgar Selzer, Karin S. Kapp

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

A comprehensive evaluation of the current national and regional radiotherapy capacity in Austria with an estimation of demands for 2020 and 2030 was performed by the Austrian Society for Radiation Oncology, Radiobiology and Medical Radiophysics (ÖGRO).

Materials and methods

All Austrian centers provided data on the number of megavoltage (MV) units, treatment series, fractions, percentage of retreatments and complex treatment techniques as well as the daily operating hours for the year 2014. In addition, waiting times until the beginning of radiotherapy were prospectively recorded over the first quarter of 2015. National and international epidemiological prediction data were used to estimate future demands.

Results

For a population of 8.51 million, 43 MV units were at disposal. In 14 radiooncological centers, a total of 19,940 series with a mean number of 464 patients per MV unit/year and a mean fraction number of 20 (range 16–24) per case were recorded. The average re-irradiation ratio was 14%. The survey on waiting times until start of treatment showed provision shortages in 40% of centers with a mean waiting time of 13.6 days (range 0.5–29.3 days) and a mean maximum waiting time of 98.2 days. Of all centers, 21% had no or only a limited ability to deliver complex treatment techniques. Predictions for 2020 and 2030 indicate an increased need in the overall number of MV units to a total of 63 and 71, respectively.

Conclusion

This ÖGRO survey revealed major regional differences in radiooncological capacity. Considering epidemiological developments, an aggravation of the situation can be expected shortly. This analysis serves as a basis for improved public regional health care planning.
Literatur
1.
Zurück zum Zitat Delaney GJ, Jacob S, Featherstone C et al (2005) The role of radiotherapy in cancer treatment. Cancer 104:1129–1137CrossRefPubMed Delaney GJ, Jacob S, Featherstone C et al (2005) The role of radiotherapy in cancer treatment. Cancer 104:1129–1137CrossRefPubMed
2.
Zurück zum Zitat Dunscombe P, Grau C, Defourny N et al (2014) Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. Radiother Oncol 112(2):165–167CrossRefPubMed Dunscombe P, Grau C, Defourny N et al (2014) Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. Radiother Oncol 112(2):165–167CrossRefPubMed
6.
Zurück zum Zitat Jack RH, Davies EA, Robinson D et al (2007) Radiotherapy waiting times for women with breast cancer: a population-based cohort study. BMC Cancer 7:71CrossRefPubMedPubMedCentral Jack RH, Davies EA, Robinson D et al (2007) Radiotherapy waiting times for women with breast cancer: a population-based cohort study. BMC Cancer 7:71CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Borras JM, Lievens Y, Dunscombe P et al (2015) The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis. Radiother Oncol 116:38–44CrossRefPubMed Borras JM, Lievens Y, Dunscombe P et al (2015) The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis. Radiother Oncol 116:38–44CrossRefPubMed
9.
Zurück zum Zitat Delaney GP, Jacob S, Featherstone SC et al (2003) Radiotherapy in cancer care: estimating optimal utilisation from a review of evidence-based clinical guidelines. Collaboration for Cancer Outcomes Research and Evaluation (CCORE) Liverpool Hospital, Sydney Delaney GP, Jacob S, Featherstone SC et al (2003) Radiotherapy in cancer care: estimating optimal utilisation from a review of evidence-based clinical guidelines. Collaboration for Cancer Outcomes Research and Evaluation (CCORE) Liverpool Hospital, Sydney
10.
Zurück zum Zitat START Trialists’ Group (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341CrossRef START Trialists’ Group (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341CrossRef
11.
Zurück zum Zitat START Trialists’ Group (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 29:371 START Trialists’ Group (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 29:371
12.
Zurück zum Zitat Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2012) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 3.0. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2012) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 3.0.
15.
Zurück zum Zitat South Australia. Dept. for Health and Ageing (2014) South Australian radiotherapy service plan 2014–2015/South Australia. Dept. for Health and Ageing South Australia. Dept. for Health and Ageing (2014) South Australian radiotherapy service plan 2014–2015/South Australia. Dept. for Health and Ageing
16.
Zurück zum Zitat Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients. The DEGRO-QUIRO. Strahlenther Onkol 8:449–460CrossRef Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients. The DEGRO-QUIRO. Strahlenther Onkol 8:449–460CrossRef
17.
Zurück zum Zitat Wong K, Delaney GP, Barton MB (2016) Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand. Radiother Oncol 119:1145–1149CrossRef Wong K, Delaney GP, Barton MB (2016) Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand. Radiother Oncol 119:1145–1149CrossRef
20.
Zurück zum Zitat Datta NR, Khan S, Marder D et al (2016) Radiotherapy infrastructure and human resources in Switzerland. Present status and projected computations for 2020. Strahlenther Onkol 192:599–608CrossRefPubMed Datta NR, Khan S, Marder D et al (2016) Radiotherapy infrastructure and human resources in Switzerland. Present status and projected computations for 2020. Strahlenther Onkol 192:599–608CrossRefPubMed
21.
Zurück zum Zitat Grau C, Defourny N, Malicki J, Dunscombe P (2014) Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiother Oncol 112:155–164CrossRefPubMed Grau C, Defourny N, Malicki J, Dunscombe P (2014) Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiother Oncol 112:155–164CrossRefPubMed
22.
Zurück zum Zitat Slotman BJ, Vos PH (2013) Planning of radiotherapy capacity and productivity. Radiother Oncol 106:266–270CrossRefPubMed Slotman BJ, Vos PH (2013) Planning of radiotherapy capacity and productivity. Radiother Oncol 106:266–270CrossRefPubMed
23.
Zurück zum Zitat Lievens Y, Deforney N, Coffey M et al (2014) Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol 112:178–186CrossRefPubMed Lievens Y, Deforney N, Coffey M et al (2014) Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol 112:178–186CrossRefPubMed
24.
Zurück zum Zitat Slotman BJ, Cottier B, Bentzen SM et al (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75(349):e1–e6 Slotman BJ, Cottier B, Bentzen SM et al (2005) Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol 75(349):e1–e6
25.
Zurück zum Zitat Slotman BJ, Leer JWH (2003) Infrastructure of radiotherapy in the Netherlands: evaluation of prognoses and introduction of a new model for determining the needs. Radiother Oncol 66:345–349CrossRefPubMed Slotman BJ, Leer JWH (2003) Infrastructure of radiotherapy in the Netherlands: evaluation of prognoses and introduction of a new model for determining the needs. Radiother Oncol 66:345–349CrossRefPubMed
26.
Zurück zum Zitat Barton MB, Hudson HM, Delaney G et al (2011) Patterns of retreatment by radiotherapy. Clin Oncol 23:10–18CrossRef Barton MB, Hudson HM, Delaney G et al (2011) Patterns of retreatment by radiotherapy. Clin Oncol 23:10–18CrossRef
27.
Zurück zum Zitat Van Harten MC, Hoebers FJP, Kross KW et al (2015) Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol 51(3):272–278CrossRefPubMed Van Harten MC, Hoebers FJP, Kross KW et al (2015) Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol 51(3):272–278CrossRefPubMed
28.
Zurück zum Zitat Elit LM, O’Leary EM, Pond GR et al (2014) Impact of wait times on survival for women with uterine cancer. J Clin Oncol 32(1):27–33CrossRefPubMed Elit LM, O’Leary EM, Pond GR et al (2014) Impact of wait times on survival for women with uterine cancer. J Clin Oncol 32(1):27–33CrossRefPubMed
29.
Zurück zum Zitat McLaughlin JM, Anderson RT, Ferketich AK et al (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500CrossRefPubMedPubMedCentral McLaughlin JM, Anderson RT, Ferketich AK et al (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Bütof R, Baumann M (2013) Time in radiation oncology – keep it short! Radiother Oncol 106:271–275CrossRefPubMed Bütof R, Baumann M (2013) Time in radiation oncology – keep it short! Radiother Oncol 106:271–275CrossRefPubMed
31.
Zurück zum Zitat Lyhne NM, Christensen A, Alanin MC et al (2013) Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002. Eur J Cancer 49:1627–1633CrossRefPubMed Lyhne NM, Christensen A, Alanin MC et al (2013) Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002. Eur J Cancer 49:1627–1633CrossRefPubMed
32.
Zurück zum Zitat GLOBOCAN (2012) http://globocan.iarc.fr/old/burden.asp?selection_pop=10040&Text-p=Austria&selection_cancer=290&Text-c=All+cancers+excl.+non-melanoma+skin+cancer&pYear=8&type=0&window=1&submit=%C2%=Execute. Accessed 29 Sept 2016 GLOBOCAN (2012) http://​globocan.​iarc.​fr/​old/​burden.​asp?​selection_​pop=​10040&​Text-p=​Austria&​selection_​cancer=​290&​Text-c=​All+cancers+excl​.​+non-melanoma+skin+ca​ncer&​pYear=​8&​type=​0&​window=​1&​submit=​%C2%=Execute. Accessed 29 Sept 2016
34.
Zurück zum Zitat Borras JM, Lievens Y, Barton M et al (2016) How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol 119:5–11CrossRefPubMed Borras JM, Lievens Y, Barton M et al (2016) How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol 119:5–11CrossRefPubMed
35.
Zurück zum Zitat Barton MB, Jacob S, Shafiq J et al (2014) Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 112:140–144CrossRefPubMed Barton MB, Jacob S, Shafiq J et al (2014) Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 112:140–144CrossRefPubMed
36.
Zurück zum Zitat Rodrıguez A, Borras JM, Lopez-Torrecilla J et al (2017) Demand for radiotherapy in Spain. Clin Transl Oncol 19(2):204–210CrossRefPubMed Rodrıguez A, Borras JM, Lopez-Torrecilla J et al (2017) Demand for radiotherapy in Spain. Clin Transl Oncol 19(2):204–210CrossRefPubMed
37.
Zurück zum Zitat Bentzen SM, Heeren G, Cottier B et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355–365CrossRefPubMed Bentzen SM, Heeren G, Cottier B et al (2005) Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355–365CrossRefPubMed
39.
Zurück zum Zitat Rosenblatt E, Izewska J, Anacak Y et al (2013) Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. Lancet Oncol 14(2):e79–e86CrossRefPubMed Rosenblatt E, Izewska J, Anacak Y et al (2013) Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. Lancet Oncol 14(2):e79–e86CrossRefPubMed
Metadaten
Titel
ÖGRO survey on radiotherapy capacity in Austria
Status quo and estimation of future demands
verfasst von
Dr. Brigitte Zurl
Anja Bayerl
Alexander De Vries
Hans Geinitz
Robert Hawliczek
Tomas-Henrik Knocke-Abulesz
Peter Lukas
Richard Pötter
Wolfgang Raunik
Brigitte Scholz
Annemarie Schratter-Sehn
Felix Sedlmayer
Dietmar Seewald
Edgar Selzer
Karin S. Kapp
Publikationsdatum
08.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 4/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1240-8

Weitere Artikel der Ausgabe 4/2018

Strahlentherapie und Onkologie 4/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.